New Study Finds Radiation Therapy May Be Optional for Some Post-Menopausal Women With Breast Cancer

Younger post-menopausal women with early-stage hormone receptor–positive (HR-positive)/human epidermal growth factor receptor 2–negative (HER2-negative) breast cancer may be able to safely omit radiation therapy, provided they continue to receive endocrine therapy, according to the IDEA clinical trial presented at the San Antonio Breast Cancer Symposium held December 5–9.

The results of the study were published December 7 in the Journal of Clinical Oncology.

The clinical trial enrolled 200 participants ages 50 to 69 who had stage 1 HR-positive, HER2-negative breast cancer. The Oncotype DX score was used to determine each patient’s risk of recurrence according to the genetic profiles of their tumors. Patients with a low risk of recurrence were eligible to skip radiation therapy after breast-conserving surgery while still receiving standard-of-care endocrine therapy for at least five years.

Among the 186 study participants, 100 percent were alive five years after surgery, and 99 percent (184 participants) were breast cancer free at this time.

Related Articles

Leave a Reply

Back to top button